Payment overview · 2025
General Payments
$774.95
33 reported records · 13 companies
Healthcare provider profile · identity verified
Hani Horani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOLINE, IL · NPI 1437237542
Verified facts
What the public records show
CMS Open Payments records show Hani Horani, MD received $774.95 in general payments during 2025 across 33 reported records.
Lilly USA, LLC accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $276.11 | 35.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $131.37 | 16.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.91 | 9.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.10 | 8.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.41 | 7.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.10 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.79 | 3.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.43 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.68 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.59 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.02 | 2.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.76 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.68 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $774.95 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $185.98 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $131.37 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.13 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.13 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $69.10 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.41 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 489 | 100 |
| Furosemide | Furosemide | 393 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 66 |
| Losartan Potassium | Losartan Potassium | 286 | 57 |
| Metformin Hcl | Metformin Hcl | 261 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 71 |
| Simvastatin | Simvastatin | 253 | 53 |
| Lisinopril | Lisinopril | 249 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 48 |
| Eliquis | Apixaban | 210 | 25 |
| Gabapentin | Gabapentin | 166 | 47 |
| Potassium Chloride | Potassium Chloride | 158 | 29 |
| Omeprazole | Omeprazole | 147 | 33 |
| Levetiracetam | Levetiracetam | 133 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 129 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 27 |
| Trazodone Hcl | Trazodone Hcl | 115 | 25 |
| Memantine Hcl | Memantine Hcl | 113 | 17 |
| Meloxicam | Meloxicam | 89 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 82 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 27 |
| Divalproex Sodium | Divalproex Sodium | 79 | 18 |
| Glipizide | Glipizide | 79 | 19 |
| Spironolactone | Spironolactone | 74 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Jardiance | Empagliflozin | 68 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | suppressed |
| Alprazolam | Alprazolam | 65 | 40 |
| Allopurinol | Allopurinol | 62 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 14 |
| Alendronate Sodium | Alendronate Sodium | 58 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | suppressed |
| Prednisone | Prednisone | 54 | 28 |
| Amiloride Hcl | Amiloride Hcl | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 13 |
| Carvedilol | Carvedilol | 53 | 11 |
| Sertraline Hcl | Sertraline Hcl | 52 | 13 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 29 |
| Famotidine | Famotidine | 49 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 45 |
| Azithromycin | Azithromycin | 47 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 13 |
| Methylprednisolone | Methylprednisolone | 46 | 39 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Nystatin | Nystatin | 21 | 13 |
| Topiramate | Topiramate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $774.95 · 33 records | Lilly USA, LLC | AIRSUPRA, AUSTEDO XR, Cologuard Collection Kit, EVENITY, FARXIGA, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, PROCLAIM, QULIPTA, Rybelsus, SYNTHROID, UBRELVY, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error